Symbolbild · KI-generiert
Knight Therapeutics Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca.
Company description as published by the issuer via TMX Money.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Knight Therapeutics Inc. | GUD | TSX | 689 Mio. USD |
| Ironwood Pharmaceuticals, Inc. | IRWD | NASDAQ | 696 Mio. USD |
| Climb Bio, Inc. | CLYM | NASDAQ | 681 Mio. USD |
| Rigel Pharmaceuticals, Inc. | RIGL | NASDAQ | 681 Mio. USD |
| Phathom Pharmaceuticals, Inc. | PHAT | NASDAQ | 698 Mio. USD |
| Nuvectis Pharma, Inc. | NVCT | NASDAQ | 678 Mio. USD |
| Faeth Therapeutics, Inc. | FTH | NASDAQ | 702 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.